老马,我家6月确诊肺腺,6月份正版帕唑帕尼 ct基本无变化; Q$ t! g9 v6 W g. y: f
7月份易瑞沙 主灶基本无变化,胸膜转移灶增大3 c0 B6 z. T3 c. T
8月份易瑞沙 主灶基本无变化,出现少量胸水 $ `% Y( u' k. x. P2 \0 m; |! H 9~10月中药 ct主灶大了近一倍,胸水增多,右下肺部分压缩不张 - b. |: D x g1 m. \( [7 i 11月份阿西替尼 ct胸水增多,几乎到胸腔一半的位置了, 2 ~& U- M$ }9 N9 V, U" c5 l 其他与10月份ct无变化" a% W$ L( E/ p: U
现在吃了7天特, 咳嗽比较厉害 7 P' i P2 Q) r& k! @/ ?4 N如不吃特,请问老马有什么建议?
Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation0 B' [' p+ x( \/ B
Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline p53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-human HER2-V659E mutation showing a phenotypic convergent evolution towards HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A clinical response both symptomatic and radiologic was achieved. HER2-V659E sensitivity to lapatinib was confirmed in the laboratory.